Key Dates
Extended Abstract Deadline
- March 10, 2023
DF/HCC Breast & Gynecologic Cancer Symposium
On Friday, April 28, 2023 the Susan F. Smith Center for Women’s Cancers and the Breast and Gynecologic Programs in the DF/HCC will sponsor a day-long symposium to highlight breast and gynecologic cancer research at Harvard.
We invite all DF/HCC researchers who are doing work in breast and gynecologic cancers, including fellows, post-docs, and junior faculty to attend and to submit abstracts.
2023 Agenda
April 28, 2023
Joseph B. Martin Conference Center
Harvard Medical School
77 Avenue Louis Pasteur
Boston MA, 02115
| 7:15 am | Sign-In, Continental Breakfast, Poster Set-Up |
| 8:00 am | Welcome/Purpose of Symposium Susan F. Smith Center Leaders |
| 8:10 am | M. PATRICIA CRONIN MEMORIAL LECTURE |
9:00 am | SESSION I: Genomics Chair: Gerburg Wulf |
9:00 – 9:45 am | 3 oral presentations (12 mins each); 3 mins questions |
Abstract #25 | Dominik Glodzik: Timing onset of homologous recombination deficiency before cancer diagnosis in BRCA1/2 mutation carriers |
Abstract #26 | Po-Han Lin: Genomics and transcriptomics landscape of early pathogenesis of the BRCA1/2-associated breast cancer |
Abstract #27 | Stefania Morganti: Clonal hematopoiesis of indeterminate potential (CHIP) after (neo)adjuvant chemotherapy (CT) versus endocrine therapy (ET) for early breast cancer (eBC): the CIRCE-eBC prospective cohort study |
9:45 am | POSTER SESSION |
10:30 am | SESSION II: Risk, Prevention & Disparities/Clinical Chair: Sara Tolaney |
| 10:30 – 11:30 am | 4 oral presentations (12 mins each); 3 mins questions |
| Abstract #5 | Cheng Peng: Regular Aspirin Use and Long-term Breast Cancer Survival |
| Abstract #19 | Joseph Dottino: Who is first in line? Trends in use of poly-ADP ribose polymerase inhibitors (PARPi) among commercially insured women with ovarian cancer |
| Abstract #22 | Filipa Lynce: A phase Ib study of sapacitabine (sapa) and olaparib (ola) in patients (pts) with BRCA1/2-mutated (BRCA1/2m) metastatic breast cancer (MBC) |
| Abstract #31 | MacLean Sellars: Personalized targeted circulating tumor DNA (ctDNA) to monitor response to combined neoantigen vaccine and immune checkpoint blockade in ovarian cancer |
| 11:30 am | J. DIRK IGLEHART, M.D., VISITING SCHOLAR LECTURE |
| 12:15 pm | Lunch and Open Posters |
| 1:15 pm | SESSION III: Drug Resistance/Animal Models |
| 1:15 – 2:15 pm | 4 oral presentations (12 mins each); 3 mins questions |
| Abstract #43 | Joshua Rivera: Single Cell Transcriptomics Reveals Putative Tumor Promoting Subpopulation in Brca1 Mutant Breast Cancer Mouse Model |
| Abstract #45 | Alexandre da Costa: The USP1 inhibitor I-138 kills BRCA1-deficient tumor cells and overcomes PARP inhibitor resistance |
| Abstract #57 | Bogang Wu: Systematic identification of pathways associated with antibody drug conjugate sensitivity in breast cancer |
| Abstract #59 | Oladapo Yeku: Antibody Drug Conjugates against MUC16 for Ovarian Cancer |
| 2:15-2:30 | 15-Minute Break |
| 2:30 pm | SESSION IV: Tumor Microenvironment/Immunology Chair: Jean Zhao |
| 2:30 – 3:30 pm | 4 oral presentations (12 mins each); 3 mins questions |
| Abstract #32 | Triet Bui: The Single-Cell Trajectory of Immune Escape During DCIS-IDC Progression |
| Abstract #34 | Maeva Chauvin: The role of cancer-associated mesothelial cells in the ovarian tumor microenvironment |
| Abstract #35 | Jenny Hogstrom: Modeling drug resistance in ER+ breast cancer using patient-derived organoid cultures and cancer-associated fibroblasts |
| Abstract #62 | Jeffrey Patterson-Fortin: Polymerase θ inhibition activates the cGAS-STING pathway in BRCA1-deficient breast cancer |
| 3:30 pm | Announcement of Awards and Adjourn |